

TABLE OF CONTENTS

FOREWORD	iii
LIST OF MEMBERS	iv
LIST OF GRAPHS AND TABLES	v
1.1 FINANCIAL SUPPORT AND CO-FINANCING	1
1.2 Overview of financial support in 1999	1
1.3 Co-financing within the Federation	3
1.4 Support to research and scientific support activities	4
2. CO-ORDINATIONS	5
3. MDT AND PREVENTION OF DISABILITIES	6
3.1 Key data for 1999	6
3.2 ILEP within the overall context of leprosy	8
3.3 New cases detected in ILEP projects in 1999	10
3.4 MDT Completion in ILEP projects in 1999	12
4. OTHER ACTIVITIES	13
The documents containing the details reported on the ILEP Questionnaires can be downloaded separately from the ILEP documentation page.	
5. COUNTRY TOTALS	
6. PROJECT TOTALS	
7. ILEP QUESTIONNAIRES	

FOREWORD

This report is a summary of activities at project, country and ILEP levels. It includes both financial and analytical data. Although most of it is concerned with MDT projects, it also includes data on other aspects of the work of Members such as socio-economic rehabilitation and tuberculosis.

Source of information:

All financial information comes from the ILEP Co-ordinate Expenditure for 1999 and previous years. Patient data from ILEP projects comes from the ILEP B Questionnaires (B1a: MDT and disability assessment, B2: Care and non-leprosy patients, B3: Socio-economic rehabilitation, B4: Combined leprosy-TB programmes). All B Questionnaires 1999 sent to the ILEP Secretariat up to the 10th October 2000 have been included in the present statistical data.

B1 Questionnaires:

611 projects completed an ILEP B Questionnaire in 1999. Data for 11 national programmes were taken from the WHO Epidemiological Records. This concerns the following countries:

1.09 CABO VERDE, 1.12 TCHAD, 1.29 GABON, 1.31 GUINEE, 1.36 COTE D'IVOIRE, GUINEA BIS, 1.90 UGANDA, 2.10 DOMINIC REP, 2.14 HAITI, 2.23 NICARAGUA, 5.07 TURKEY

Data for a further 35 projects was taken from the most recently available data (1998 ILEP B1 Questionnaires), because there was no report received for 1999.

Accuracy of data

The data is received from ILEP Members, either as hard copy or through e-mail. Members are responsible for checking the accuracy of data coming from the field.

Every effort is made in our office to avoid data-entry error. However some errors may still occur. Please inform us should you notice any mistake. One particular area of concern to us is the possibility of double counting of patients in cases of overlapping projects. Our computer programme can deal with this problem, provided we are aware of the existence of such a situation. Please note that the tables E to H in section 6 contain data that may overlap. For this reason country totals are not included in these tables. Totals may be found in the country tables, section 5 tables A to D, which do not include the duplicated data.

Feed-back

We will be happy to receive your comments and reactions to this annual report. Please do not hesitate to contact us.

Internet

This document, as well as the complete project profiles and all ILEP questionnaires can be downloaded from the ILEP web site ilep@ilep.org.uk in a number of formats.

ILEP MEMBER ASSOCIATIONS

With the initials used in this document

- **AFRF** Association Française Raoul Follereau France
- **AIFO** Amici di Raoul Follereau Italy
- **ALES** Aide aux Léproux Emmaüs-Suisse Suisse
- **ALM** American Leprosy Missions USA
- **DAHW** Deutsches Aussätzigen-Hilfswerk Germany
- **DFB** Damien Foundation Belgium
- **FL** Fondation Luxembourgeoise Raoul Follereau Luxembourg
- **FO** Fondation Père Damien Belgium
- **ICLL** Institut Cardinal Léger contre la Lèpre Canada
- **LPRA** British Leprosy Relief Association United-Kingdom
- **LWM** Leonard Wood Memorial USA
- **NLR** Netherlands Leprosy Relief Association Netherlands
- **OM** Fondation du CIOMAL Switzerland
- **SF** Fontilles, Lucha contra la Lepra Spain
- **SJ** Sasakawa Memorial Health Foundation Japan
- **SLC** Le Secours aux Léproux Canada
- **TLMI** The Leprosy Mission International United-Kingdom
- **TLRA** Taiwan Leprosy Relief Association Taiwan

LIST OF GRAPHS AND TABLES

Graphs		Page
1	Number of projects by type of activities	1
2	Trend in support of ILEP Members to leprosy work 1989-1999	2
3	% grants towards own projects compared with grants to other co-ordinators	3
4	Number of projects according to number of Members giving support	3
5	Distribution of ILEP grants according to number of Members	4
6	% funds allocated to the different categories of research	4
7	Number of national and state co-ordinations in India and Brazil	5
8	Number of projects co-ordinated related to patients treated in these projects	5
9	Case detection and prevalence rate 1995-1999 3 graphs	7
10	Registered and new patients in ILEP projects compared to world figures	9
11	Total registered and new cases (1995-1999)	10
12	Children among newly detected cases (1995-1999)	10
13	Newly detected cases with WHO grade 1 and 2 disability	11
14	Disability assessment on newly detected cases (1996-1999)	11
15	Trend in MDT completion rates from (1994-1999)	12

Tables

1	Members' support to leprosy work in 1999	1
2	Details of support of ILEP Members to leprosy work 1988-1999	2
3	Details of the different research categories	4
4	ILEP global indicators end 1999	6
5	Registered prevalence of leprosy and detection rates comparing world and ILEP figures for selected countries.	8
6	Completion of MDT by key countries for 1999	12
7	Single dose ROM 1998-1999	12
8	Socio-economic activities	13
9	Care and hospital admissions key figures	13
10	Tuberculosis activities key figures 1999	13

1. FINANCIAL SUPPORT AND CO-FINANCING


1.1 OVERVIEW OF FINANCIAL SUPPORT IN 1999

Table 1: Members' support to leprosy work in 1999

	Support to field projects	Support to research*	Indirect Field support	Total support
No. of Countries	98			98
No. of Projects	1 161	61	39	1 261
DAHW	11 862 820	21 915	159 731	12 044 466
TLMI	11 224 165	4 936	0	11 229 101
NLR	5 666 804	678 284	260 661	6 605 749
AFRF	5 301 509	687 569	159 760	6 148 838
DFB	5 233 264	278 012	7 148	5 518 424
ALM	3 030 496	97 417	258 576	3 386 489
LPRA	1 784 069	471 977	527 451	2 783 497
ALES	2 579 767	42 813	14 882	2 637 462
AIFO	2 506 935	35 141	57 713	2 599 789
SJ	1 462 728	661 074	413 355	2 537 157
FL	920 344	148 368	0	1 068 712
SLC	795 365	39 605	22 963	857 933
SF	530 579	0	0	530 579
ICLL	462 679	0	4 763	467 442
OM	269 855	64 281	0	334 136
LWM	30 000	88 747	0	118 747
FO	68 861	0	0	68 861
TOTAL	53 730 240	3 320 139	1 887 003	58 937 382

* includes other scientific activities such as Congresses and Journals

Graph 1: Number of projects by type of activities



Different types of projects overlap, the same project may belong to several categories.


MTD : All projects with a MDT component	657 Prj	\$ 31 097 680
SER : Socio-economic rehabilitation component	280 Prj	\$ 11 581 828
MDT/TB : All projects with TB component	142 Prj	\$ 11 881 144
POD/CARE : All projects with a POD/CARE component	454 Prj	\$ 21 060 799
RESEARCH: All research and scientific support projects	61 Prj	\$ 3 320 139

⚡ Please refer to ILEP Co-ordinate Expenditure 1999 for complete financial details

Table 2: Details of support of ILEP members to leprosy work 1988-1999

Year	Field related expenditure	Research and scientific support	Total Expenditure	% Research
1988	53 793 904	5 801 017	59 594 921	9.73%
1989	54 248 242	5 769 243	60 017 485	9.61%
1990	63 029 709	6 526 941	69 556 650	9.38%
1991	66 814 109	5 653 075	72 467 184	7.80%
1992	71 501 656	5 605 249	77 106 905	7.27%
1993	66 037 765	4 554 373	70 592 138	6.45%
1994	55 126 596	4 109 765	59 236 361	6.94%
1995	55 514 077	3 662 499	59 176 576	6.19%
1996	56 046 899	3 547 333	59 594 232	5.95%
1997	58 182 653	2 815 039	60 997 692	4.61%
1998	57 908 015	3 081 357	60 989 372	5.05%
1999	55 617 243	3 320 139	58 937 382	5.63%
Total	713 820 868	54 446 030	768 266 898	7.09%


Graph 2: Trend in support of ILEP Members to leprosy work 1989-1999




✎ For further information on research activities supported by ILEP Members in 1999, please refer to the ILEP Research Directory 1999

1.2 CO-FINANCING WITHIN THE FEDERATION

Graph 3: % grants towards own projects compared with grants to other co-ordinators' projects




Graph 4: Number of projects according to number of Members giving support



Out of the 1261 projects supported by ILEP Members in 1999, 1094 projects were financed by one Member only, whilst 2 projects were supported by 8 Members .

Graph 5: Distribution of ILEP Grants according to number of Members giving support




Of the \$ 58 937 382 granted by ILEP Members in 1999, 68.9% was allocated to projects supported by one Member only, whilst only 1.5% of the funds was allocated to projects supported by 8 Members.

1.3 SUPPORT TO RESEARCH AND SCIENTIFIC SUPPORT ACTIVITIES

Table 3: Details of the different research categories

Research categories	No. of projects	Grants in US \$
Applied Research	25	1 091 389
Basic Research	14	973 240
Institutions	6	326 748
Miscellaneous Leprosy Research	2	82 192
Non-Leprosy Research	3	258 057
Scientific Support	11	588 513
Total	61	3 081 357

Graph 6: % of funds allocated to the different categories of research




For further information on research activities supported by ILEP Members in 1999, please refer to the ILEP Research Directory 1999

2. CO-ORDINATIONS


Co-ordinations are as approved by the December 1999 meeting.

Graph 7: Number of national and state co-ordinations (India and Brazil).



The National Co-ordinations are divided according to the number of patients registered for MDT. Since Brazil has been broken down into States the National Co-ordination is not represented here. The above graph only includes the Co-ordinations for which there was patient data in 1999. Other co-ordinations for which no data was available were not included in the present graph (AFRF: 4 - AIFO: 2 - ALM: 4 - DAHW: 11 - NLR: 1 - OM: 2 - SF: 1 - SJ: 1).

Graph 8: Number of projects co-ordinated related to patients treated in these projects



3. MDT AND PREVENTION OF DISABILITIES

3.1 KEY DATA FOR 1999

Table 4: ILEP global indicators end 1999

657 projects in 83 countries have reported	
Questionnaires ILEP B: 611, WHO national programme data: 11	
Questionnaires 1998 ILEP B: 35	
* Total combined population of all ILEP Projects	2 596 263 172
* Total number of patients registered for treatment at year end	379 650
* Total number of newly detected cases during 1999	353 629
% MB on all new cases	45%
* Total number of children among the newly detected cases	50 243
% children on all new cases	14%
* New cases with disability assessment at detection	277 279
% new cases with disability assessment on all new cases	78%
* New cases with disability 2 amongst all those assessed	24 514
% on all new cases assessed	9%
% on all new cases	7%
* MDT Completion	
PB Patients having completed MDT as prescribed	128 099
completion rate PB	88%
MB Patients having completed MDT as prescribed	95 824
completion rate MB	78%

* The total population figure for ILEP is obtained by adding the populations of the individual projects catchment areas.

On the following page there are three graphs showing the prevalence and case detection rates in ILEP supported projects. The graphs show the rates in all ILEP projects and in all projects excluding India and in India only.

A slight decrease is observed in the case detection rate in 1999, compared to 1998. It is, however still above the level of the previous years. It is important to note that when India is excluded from the statistics, the annual case detection rate has been on the rise since 1996. In India an important increase in the case detection rate has been noted in 1998, mainly due to the modified Leprosy Elimination Campaigns. These campaigns did not take place in 1999, or at least not on the same scale. This is probably the main explanation for the lower rate of 1999.


A slow downward trend is observed in the registered prevalence rate, more pronounced in India in 1999 than in the other projects, probably for the same reasons as cited above. If one looks at the absolute numbers instead of the rates (graph 11 page 10), one sees that the number of registered cases did actually increase in 1999, while the number of newly detected cases decreases.

These differences are due to the higher size of the population covered; this coverage increased by 9.2% in 1999, compared to 1998.


Graph 9: Case detection and prevalence rate 1994-1999

These rates relate to patients in projects supported within any given year. Although the great majority of projects are supported over all the years specified, it is not the case for all projects. To produce global rates, the project populations are added together.


All ILEP Supported Projects



All ILEP Supported Projects Excluding Data from India



Data from Projects in India Only



3.2 ILEP WITHIN THE OVERALL CONTEXT OF LEPROSY

Table 5: Registered prevalence of leprosy and detection rates comparing world and ILEP figures for selected countries (GAEL groups 1, 2 and 3).

Country	World Figures 1999/2000				ILEP Projects 1999			
	Prevalence		Case-detection		Prevalence		Case-detection	
	All registered	Rate per 10 000	All new detected	Rate per 100 000	All registered	Rate per 10 000	All new detected	Rate per 100 000
India	495 073	5.0	537 956	54.3	148 601	6.9	168 370	77.9
Brazil	78 068	4.3	42 055	25.9	69 609	5.0	41 537	30.1
Myanmar	28 404	5.9	30 479	62.9	28 481	5.9	29 765	61.8
Indonesia	23 156	1.1	17 477	8.3	19 608	1.1	16 344	9.3
Nepal	13 572	5.7	18 693	78.7	10 330	8.0	10 480	81.3
Bangladesh	11 092	0.9	14 336	11.4	8 875	1.6	10 545	19.4
Madagascar	7 865	4.7	8 704	51.6	8 695	5.6	9 147	59.0
Ethiopia	7 764	1.3	4 457	7.4	2 786	0.5	5 974	9.7
Nigeria	7 707	0.6	7 918	6.3	7 994	0.7	8 597	7.5
Mozambique	7 403	3.9	5 488	28.7	6 732	3.5	5 485	28.7
R. D. du Congo	5 031	1.0	4 221	8.6	4 192	1.1	3 234	8.5
Tanzania	4 701	1.4	5 081	15.4	4 701	1.3	5 105	14.5
Philippines	4 251	0.6	3 390	4.5	4 785	0.6	3 737	4.6
Angola	3 075	2.5	1 840	14.9	3 075	2.4	1 840	14.4
Egypt	3 020	0.5	1 472	2.2	3 112	0.5	1 532	2.6
Colombia	2 933	0.8	607	1.7	1 963	0.5	648	1.6
Niger	2 375	2.3	1 907	18.2	2 417	2.3	1 907	17.9
Sudan	2 332	0.8	2 426	8.3	2 888	1.5	2 689	13.9
Thailand	2 291	0.4	864	1.4	2 291	0.4	864	1.4
Vietnam	2 087	0.3	1 795	2.3	1 745	0.3	1 400	2.1
Argentina	2 000	0.5	471	1.3	1 439	0.8	476	2.8
Cote d'Ivoire	1 978	1.3	1 719	10.9	1 978	1.4	1 719	11.8
Pakistan	1 905	0.1	927	0.6	2 067	0.1	975	0.7
Mali	1 793	1.5	1 786	14.7	1 793	1.8	1 786	17.8
Cameroun	1 588	1.1	1 337	9.1	2 866	2.0	1 346	9.6
Guinee Conakry	1 559	2.0	2 475	32.0	1 559	2.1	2 475	33.6
Sierra Leone	1 481	3.1	413	8.5	252	0.5	250	5.4
Ghana	1 419	0.7	1 620	8.4	1 419	0.7	1 620	8.3
Sri Lanka	1 260	0.7	1 757	9.4	1 260	0.7	1 757	9.4
Uganda	1 180	0.5	888	4.1	1 180	0.6	888	4.2
Gabon	1 047	7.29	26	1.8	1 047	8.7	26	2.2
Burkina Faso	940	0.8	879	7.5	1 062	1.0	801	7.3
Tchad	749	1.1	1 030	14.5	819	1.0	1 096	14.0
Paraguay	652	1.2	357	6.7	1 065	1.3	661	8.2
Yemen Rep	607	0.3	561	3.2	718	0.4	561	3.2
Cambodge	584	0.5	790	7.2	584	0.5	790	6.9
Centrafrique	549	1.5	422	11.8	549	1.6	422	12.0
Papua NG	504	1.1	713	15.5	504	1.0	713	14.5
Benin	480	0.8	619	10.2	480	0.8	619	9.7
Senegal	468	0.5	474	5.1	468	0.5	474	5.1
Congo	464	1.6	53	1.8	539	1.9	70	2.5
Liberia	330	1.0	200	6.0	869	2.7	570	17.8
PDR Laos	282	0.5	177	3.2	282	0.6	177	3.6
Guinea bissau	144	1.2	53	4.6	144	1.2	53	4.5
Gambia	132	1.1	115	9.4	68	0.5	59	4.3
Haiti	103	0.1	45	0.6	103	0.1	45	0.6
Listed	736 398		731 073		367 994		349 629	
Others	16 865		7 211		11 656		4 000	
World/ILEP	753 263	1.25	738 284	12.3	379 650	1.46	353 629	13.6

Comments on Table 5

The countries selected in Table 5 are those in the GAEL group 1, 2 and 3 countries where there is data reported in 1999. The table is sorted by the total number of patients registered in the country according to WHO. WHO figures are taken from Weekly epidemiological record 14 July 2000 or from the WHO web site where the latest available data can be found.


The figure for the number of patients registered in Ethiopia in ILEP projects is possibly lower than it should be. This is due to a difference of reporting criteria used in the country.

In the ILEP projects 26 of the 46 countries have a registered prevalence rate (and usually a case detection rate) > 1.0 per 10 000. While the relative part of ILEP in terms of the number of registered patients is 50% at global level, it is far below that limit in India and Ethiopia. In Ethiopia this might be explained by a reporting problem.

The population used for the calculation of rates in ILEP projects is obtained by adding together the populations of all the projects within the countries whilst WHO uses the whole population of the country. Often ILEP Members' projects cover specific areas where leprosy is highly endemic; thus prevalence rates are higher in ILEP projects.

It should also be noted that the ILEP reporting year is different from WHO. The source of the ILEP data is the B1 Questionnaire, which records data as at the 31 December 1999. WHO data is added continuously throughout the year. In cases where ILEP does not cover the whole country the projects supported are added together to produce the figures.


Graph 10: Registered and New Patients in ILEP projects compared to World Figures



There is a progressive increase in the part taken by ILEP in the numbers of registered and newly detected patients.


3.3 NEW CASES DETECTED IN ILEP PROJECTS

Graph 11: Total registered and new cases (1995-1999)



Since 1998, the number of new cases detected and the number of cases registered at the end of the year are approximately equal. The number of registered cases has not decrease since 1997. The number of newly detected cases only decreased marginally.


Graph 12: Children among newly detected cases (1995 - 1999)



The percentage of children among newly detected cases has remained relatively stable over the last 3 years.


For further details on new cases and detection rates please consult Sections 5 and 6

Graph 13: Newly detected cases with WHO grade 1 & 2 disability



Prior to 1996 the ILEP B questionnaire did not collect data on grade 1 disability.

Graph 14: Disability assessment on newly detected cases (1996-1999)




The percentage of new cases who have undergone a disability assessment at detection is now 78%. The ILEP target as adopted in the ILEP Strategy plan is 100 %.

Although the situation improves progressively, much has still to be done if one wants to reach the ILEP target of 100% disability assessment among the new cases.

3.4 MDT COMPLETION IN ILEP PROJECTS

Graph 15: Trend in MDT completion rates from 1994 to 1999



Completion rates have increased significantly in 1999. For the MB patients the shortening of the duration of treatment may have played a role in that improvement. This explanation is not valid for the

Table 6: Completion of MDT in the top ten countries from Table 5 (page 8)

Countries	Start PB	Completed PB	PB Rate %	Start MB	Completed MB	MB Rate %
INDIA	75 063	73 677	98.2	34 022	31 101	91.4
BRAZIL	16 125	12 930	80.2	14 361	8 486	59.1
MYANMAR	7 091	6 736	95.0	5 493	4 944	90.0
INDONESIA	4 223	3 272	77.5	12 113	9 578	79.1
NEPAL	1 018	722	70.9	2 912	1 921	66.0
BANGLADESH	6 619	5 955	90.0	3 132	2 849	91.0
MADAGASCAR	4 142		0.0	1 064		0.0
ETHIOPIA	999	940	94.1	4 708	3 820	81.1
NIGERIA	1 884	1 728	91.7	5 442	4 540	83.4
MOZAMBIQUE	2 627	2 461	93.7	9 412	8 855	94.1
Total	119 791	108 421	90.5	92 659	76 094	82.1

Table 7: Single dose ROM 1998 - 1999

	Countries	1998	1999
Although given to some patients in 12 countries, the use of ROM remains practically limited to India, Brazil and Bangladesh.	BANGLADESH	285	575
	BRAZIL	263	406
	CAMEROUN	0	2
	INDIA	1992	11 943
	INDONESIA	79	2
	MADAGASCAR	12	40
	NEPAL	33	32
	NIGER	0	49
	PAKISTAN	0	11
	ST LUCIA	0	1
	SUDAN	0	7
	ZAMBIA	0	3
Total		2 664	13 071

The new single dose ROM was reported to be used by 241 projects in 12 countries. The project co-ordinators involved were AFRF, AIFO, ALES, ALM, DAHW, DFB, LEPR, NLR, SF and TLM

4. OTHER FIELD ACTIVITIES & SERVICES

4.1 Socio-economic activities

280 projects in 39 countries reported the following SER activities:

Table 8: Socio-economic activities (SER) Key figures for 1999

Services	Patients	Families	Total Interventions
Economic	14 204	12 343	26 547
Housing	2 432	1 538	3 970
Education	8 281	8 917	17 198
Welfare	25 017	25 088	50 105
Total	49 934	47 886	97 820

☞ Refer to table C in section 5 for country details and table G in section 6 for project details, on socio-economic activities.

4.2 Care and Hospital admissions

454 projects in 53 countries reported 305 086 ex-patients on their care after cure register and 107 908 of these were said to be in need of protective footwear.

Table 9: Care and Hospitalisation Key figures 1999

Services	Admissions	Surgeries	Total
Eye care	29 758	2 704	32 462
Reaction	8 782	1 076	9 858
Ulcer	46 220	25 115	71 335
Surgery	5 900	4 157	10 057
Other	46 669	6 647	53 316
Total	137 329	39 699	177 028

☞ Refer to table B in section 5 for country details and table F in section 6 for project details on Care and Hospital admissions

4.3 Combined Leprosy-Tuberculosis programmes

143 projects in 31 countries reported 435 923 newly detected tuberculosis patients never treated before.

Table 10: Tuberculosis activities Key figures 1999

Courses	Patients	Cured	Completed
Short	222 327	124 593	20 691
Retreatment	23 761	12 159	1 924
Total	246 088	136 752	22 615

☞ Refer to table D in section 5 for country details and table H in section 6 for project details on Tuberculosis activities.